2
Total investments
1
Early stage
0
Mid stage
1
Late stage
12y
Years active
Portfolio
2 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Executive board member
Nov 2018
Electroducer: a device to secure and optimize TransHeart Valve (THV) & Percutaneous Coronary Interventions (PCI), a rapid Pacing using Left Ventricular Guidewire.
Mechanical Device for simplified cardiac procedures:
- Patents pending
- Class II device
Provides Temporary Pacing without Pace Maker:
- During THV (TAVI, TMVR, TTVR)
- During complex PCI (Rotablator, STEMI)
Plug on usual interventions devices:
- Usual introducers
Board member
May 2014
OpSens focuses mainly in interventional cardiology. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of 200,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.
OpSens has recently received FDA clearance and Health Canada approval to commercialize the SavvyWire for transcatheter aortic valve replacement procedures (TAVR). This unique guidewire is a 3-in-1 solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement during the procedure, and reliable left ventricular pacing without the need for adjunct devices or venous access.
The TAVR procedure is growing rapidly globally, driven by the aging population and recent studies that demonstrate its benefits for a broader array of patients. The global TAVR market is currently estimated at over 200,000 procedures and is expected to reach 400,000 in 2027.
OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.
Experience · 3 entries
All (3)
Investments (2)
Board (2)
2018
Executive board member
Nov 2018
Electroducer: a device to secure and optimize TransHeart Valve (THV) & Percutaneous Coronary Interventions (PCI), a rapid Pacing using Left Ventricular Guidewire.
Mechanical Device for simplified cardiac procedures:
- Patents pending
- Class II device
Provides Temporary Pacing without Pace Maker:
- During THV (TAVI, TMVR, TTVR)
- During complex PCI (Rotablator, STEMI)
Plug on usual interventions devices:
- Usual introducers
2014
Board member
May 2014
OpSens focuses mainly in interventional cardiology. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of 200,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.
OpSens has recently received FDA clearance and Health Canada approval to commercialize the SavvyWire for transcatheter aortic valve replacement procedures (TAVR). This unique guidewire is a 3-in-1 solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement during the procedure, and reliable left ventricular pacing without the need for adjunct devices or venous access.
The TAVR procedure is growing rapidly globally, driven by the aging population and recent studies that demonstrate its benefits for a broader array of patients. The global TAVR market is currently estimated at over 200,000 procedures and is expected to reach 400,000 in 2027.
OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.
2002
Sales rep & product specialist
Jul 2002
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and www.facebook.com/AbbottCareers, on Instagram @AbbottGlobal, and on X @AbbottNews.
We invite you to explore opportunities at Abbott, to see if your talents and career aspirations may fit with our openings. An equal opportunity employer, Abbott welcomes and encourages diversity in our workforce.
Terms of Use: https://www.abbott.com/social-media-terms-of-use.html
Privacy Policy: https://abbo.tt/privacy
Similar investors
Manufacturing early-stage investors in France
Investor lists
Lists that match Lucien's portfolio
- Manufacturing early-stage investors in France361 investors
- Early-stage startup investors in France2,582 investors






